NVCR · NovoCure Ltd
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Leonard Frank X |
Chief Executive Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Ordinary Shares
|
1,905 |
| 2026-06-30 | Puri Michal Nath |
Chief Human Resources Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Ordinary Shares
|
1,905 |
| 2026-06-30 | Ben Arye Barak |
General Counsel |
Award↑
Filing footnotes — Ordinary Shares (Direct)
The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Ordinary Shares
|
1,299 |
| 2026-06-30 | Danziger Asaf |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Ordinary Shares
|
268 |
| 2026-06-04 | Leonard Frank X |
Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $17.665 USD to $18.37 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
34,273 |
| 2026-06-03 | Ocean Allyson J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | Hung David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | Madden Martin J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | Stafford Kristin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | Stafford Kristin |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | VERNON W ANTHONY |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | VERNON W ANTHONY |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | Madden Martin J. |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | LEUNG GABRIEL |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | LEUNG GABRIEL |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | Scannell Timothy J |
President and COO |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | HILLEMAN JERYL L |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | Scannell Timothy J |
President and COO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Stock Option (Right to Buy)
|
16,999 |
| 2026-06-03 | HILLEMAN JERYL L |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | Hung David |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-03 | Ocean Allyson J |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Ordinary Shares
|
11,610 |
| 2026-06-02 | Stafford Kristin |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-06-02 | Hung David |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-06-02 | HILLEMAN JERYL L |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-06-02 | Ocean Allyson J |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-06-02 | Scannell Timothy J |
President and COO |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-06-02 | LEUNG GABRIEL |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-06-02 | VERNON W ANTHONY |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
2,945 |
| 2026-04-28 | VERNON W ANTHONY |
Director |
Convert↓
|
Stock Option (Right to Buy)
|
21,500 |
| 2026-04-28 | VERNON W ANTHONY |
Director |
Convert↑
|
Ordinary Shares
|
21,500 |
| 2026-03-05 | Paravasthu Mukund |
Chief Operating Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was executed in multiple trades at prices ranging from $13.74 USD to $14.07 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
43,246 |
| 2026-03-04 | Paravasthu Mukund |
Chief Operating Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
5,377 |
| 2026-03-04 | Brackmann Christoph |
Chief Financial Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
6,412 |
| 2026-03-04 | Weinberg Uri |
Chf Medical and Innovation Ofr |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
6,412 |
| 2026-03-04 | Puri Michal Nath |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
1,100 |
| 2026-03-04 | Leupin Nicolas |
Former Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
1,100 |
| 2026-03-04 | Cordova Ashley |
Former Chief Executive Officer |
Tax↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). |
Ordinary Shares
|
17,638 |
| 2026-03-04 | Leonard Frank X |
Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
5,607 |
| 2026-03-03 | Brackmann Christoph |
Chief Financial Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
Ordinary Shares
|
55,137 |
| 2026-03-03 | Brackmann Christoph |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Stock Option (Right to Buy)
|
80,674 |
| 2026-03-03 | DOYLE WILLIAM F |
Director, Executive Chairman |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
Ordinary Shares
|
200,000 |
| 2026-03-03 | DOYLE WILLIAM F |
Director, Executive Chairman |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents vesting of performance-based restricted stock units. |
Ordinary Shares
|
200,284 |
| 2026-03-03 | DOYLE WILLIAM F |
Director, Executive Chairman |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Stock Option (Right to Buy)
|
258,445 |
| 2026-03-03 | Ben Arye Barak |
General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Stock Option (Right to Buy)
|
73,340 |
| 2026-03-03 | Ben Arye Barak |
General Counsel |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
Ordinary Shares
|
50,125 |
| 2026-03-03 | Leonard Frank X |
Chief Executive Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
Ordinary Shares
|
150,000 |
| 2026-03-03 | Weinberg Uri |
Chf Medical and Innovation Ofr |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Stock Option (Right to Buy)
|
73,340 |
| 2026-03-03 | Leonard Frank X |
Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Stock Option (Right to Buy)
|
216,388 |
| 2026-03-03 | Paravasthu Mukund |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Stock Option (Right to Buy)
|
7,518 |
| 2026-03-03 | DOYLE WILLIAM F |
Director, Executive Chairman |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price. |
Ordinary Shares
|
21,330 |